Search
Quazepam
go.drugbank.com/drugs/DB01589ApprovedIllicitIt was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … It can be administered topically or orally and is only indicated in patients aged 12 years or older.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalSingle doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. … Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Vilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.
Nefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnOn May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. … Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury.
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] On November 3rd 2022, Health Canada also approved the Moderna Bivalent Vaccine as a booster shot in individuals 18 years of age or older.[L43862] … [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalIt is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.